Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Director Purchases $2,336,000.00 in Stock

Key Points

• Kevin Tang, the Director of Aurinia Pharmaceuticals, acquired 200,000 shares of the company at an average price of $11.68 per share, totaling $2.34 million and increasing his ownership by 1.80%.
• Aurinia Pharmaceuticals reported quarterly earnings of $0.16 per share, missing analysts' expectations, but had a revenue of $70.01 million, exceeding projections of $64.27 million.
• Institutional investors hold approximately 36.83% of Aurinia's stock, with recent activity indicating growing interest among hedge funds in the biotechnology company.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP Director Kevin Tang acquired 200,000 shares of the stock in a transaction on Tuesday, August 5th. The shares were purchased at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the transaction, the director owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. This represents a 1.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Kevin Tang also recently made the following trade(s):

• On Monday, August 4th, Kevin Tang purchased 100,000 shares of Aurinia Pharmaceuticals stock. The shares were bought at an average price of $11.34 per share, with a total value of $1,134,000.00.
• On Friday, August 1st, Kevin Tang purchased 1,000,000 shares of Aurinia Pharmaceuticals stock. The shares were bought at an average price of $10.12 per share, with a total value of $10,120,000.00.

Aurinia Pharmaceuticals Trading Down 0.5%

NASDAQ AUPH traded down $0.06 on Friday, reaching $11.37. The company had a trading volume of 2,496,968 shares, compared to its average volume of 2,572,066. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 26.44 and a beta of 1.23. Aurinia Pharmaceuticals Inc has a fifty-two week low of $5.29 and a fifty-two week high of $11.80. The business has a 50 day moving average of $8.70 and a two-hundred day moving average of $8.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The company had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Analyst Upgrades and Downgrades

AUPH has been the subject of several research analyst reports. Royal Bank Of Canada upped their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. HC Wainwright reiterated a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AUPH. Raymond James Financial Inc. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at $215,000. American Century Companies Inc. boosted its position in Aurinia Pharmaceuticals by 124.2% during the fourth quarter. American Century Companies Inc. now owns 171,590 shares of the biotechnology company's stock valued at $1,541,000 after acquiring an additional 95,066 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at $201,000. LPL Financial LLC boosted its position in Aurinia Pharmaceuticals by 21.8% during the fourth quarter. LPL Financial LLC now owns 46,600 shares of the biotechnology company's stock valued at $418,000 after acquiring an additional 8,327 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Aurinia Pharmaceuticals by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock valued at $15,535,000 after acquiring an additional 112,113 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.